1Huang X,Lu CH,Xie HW,et al.Blood lose measurement for TURP by means of standard tube control. Chin J Urol,1990,11:192.黄循,陆灿辉,谢会文,等.标准管对照法测定TURP术中失血量.中华泌尿外科杂志,1990,11:192.
4Bihrle R, Fostetr RS, Sanghvi NT, et al. High intensity focused ultrasound for the treatment of benign prostatic hyperpleaia: early United States clinical experience.J Urol,1994,151:1271-1275.
1Costello AJ, Bowsher WG, Bolton DM, et al. Laser ablation of the prostate in patients with benign prostatic hypertrophy. Br J Urol, 1992, 69: 603-608.
2Kuntzman RS, Malek RS, Barrett DM, et al. High-power (60- watt) potassium-titanyl-phosphate laser vaporization prostatectomy in living canines and in human and canine cadavers. Urology, 1997, 49 : 703-708.
5Jacques SL. Laser-tissue interaction: photochemical, pbotother- mal, and photomechanical. Surg Clin North Am, 1992, 72: 531-558.
6Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic ob- struction ( BPH guidelines). Eur Urol, 2004, 46 : 547-554.
7Reich O, Baehmann A, Siehels M, et al. itigh power (80W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol, 2005, 173: 158-160.
8Ruszat R, Wyler S, Forster T, et al. Safety and effectiveness of photoseleetive vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol, 2007, 51 : 1031-1041.
9Hori Y, Kuromatsu I, Sugimura Y. Safety and effectiveness of photoseleetive vaporization of the prostate (PVP) in patients with oral anticoagulant therapy. Hinyokika Kiyo, 2008, 54: 651- 656.
10Ruszat R, Wyler S, Forster T, et al. Complications of photose- lective vaporization of the prostate. Eur Urol Suppl, 2007, 6: 136.
